Filtered By:
Drug: Clopidogrel
Procedure: Coronary Artery Bypass Graft

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study
Conclusions In patients with ACS, higher levels of GDF-15 are associated with raised risks of all types of major non-CABG-related bleeding, spontaneous MI, and stroke as well as CV and total mortality and seem to improve risk stratification for CV-mortality and major bleeding beyond established risk factors. Clinical Trial Registration www.clinicaltrials.gov; NCT00391872.
Source: European Heart Journal - April 20, 2016 Category: Cardiology Authors: Hagström, E., James, S. K., Bertilsson, M., Becker, R. C., Himmelmann, A., Husted, S., Katus, H. A., Steg, P. G., Storey, R. F., Siegbahn, A., Wallentin, L., for the PLATO Investigators Tags: Acute coronary syndromes Source Type: research

Cost-Effectiveness of 12-Month Treatment With Ticagrelor Compared With Clopidogrel in the Management of Acute Coronary Syndromes.
CONCLUSIONS: When assessed from the perspective of the Australian health care system, ticagrelor is likely to be cost-effective compared with clopidogrel in preventing downstream morbidity and mortality associated with ACS. PMID: 23891361 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - July 26, 2013 Category: Drugs & Pharmacology Authors: Liew D, De Abreu Lourenço R, Adena M, Chim L, Aylward P Tags: Clin Ther Source Type: research

054 * hybrid surgery in patients with concomitant critical coronary and carotid artery lesions
Conclusions: Hybrid surgery in patients with concomitant critical coronary and carotid artery lesions is a safe and very effective procedure that reduces the number of complications during the surgical treatment of this severe cohort of patients.
Source: Interactive CardioVascular and Thoracic Surgery - September 18, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Edemskiy, A., Chernyavskiy, A., Vinogradova, T. E., Chernyavskiy, M. Tags: Controversies in coronary artery surgery II Source Type: research

Abstract 132: The POWR Survey: Patient and Physician Perspectives on Outcomes Weighting in Revascularization. Session Title: Poster Session I
Conclusions: Patients and physicians agree on which outcomes are most (death and stroke)and least impactful (incision scar), but there is a lot of variability in between supporting the reporting of more adverse outcomes and not just those included in MACE.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Pandit, J. A., Gupta, V., Boyer, N., Ports, T. A., Yeghiazarians, Y., Boyle, A. J. Tags: Session Title: Poster Session I Source Type: research

Simultaneous Carotid Artery Stenting and Heart Surgery: Expanded Experience of Hybrid Surgical Procedures
Conclusions Same-day hybrid approach appeared safe in terms of early and long-term results not only for CAS and isolated CABG but also for CAS and noncoronary isolated procedures. In complex cases, the rate of stroke and myocardial infarction seemed low; in-hospital mortality, as expected, was higher. Long-term survival appeared similarly satisfactory, thus confirming the hybrid approach as a valid therapeutic option for all patients with significant internal carotid artery stenosis associated with coronary and other cardiac lesions, at least for noncomplex cases.
Source: The Annals of Thoracic Surgery - February 19, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research

Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Abstract Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS). Our aim was to determine whether patients sustaining ACS while on chronic clopidogrel therapy have a worse prognosis than clopidogrel-naïve patients. A total of 5,386 consecutive ACS patients were prospectively characterised and followed-up for 30 days. Of them, 680 (13 %) were treated with clopidogrel prior to the index ACS. Major adverse cardiovascular events (MACE) were defined as death, recurrent ACS, stroke and/or sten...
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Asher E, Fefer P, Sabbag A, Herscovici R, Regev E, Mazin I, Shlomo N, Zahger D, Atar S, Hammerman H, Polak A, Beigel R, Matetzky S, PLATIS (Platelets and Thrombosis in Sheba) Study Group Tags: Thromb Haemost Source Type: research

Safety outcomes of anti-platelet therapy post coronary artery bypass graft surgery: A systematic review and network meta-analysis of randomized control trials
CONCLUSION: No significant difference was found between monotherapy or dual-antiplatelet therapy for the major bleeding risk safety outcome, however DAPT was found to have a significantly higher rate of minor bleeding complications post-CABG. DAPT should be considered as the antiplatelet modality of choice post-CABG.PMID:36803180 | DOI:10.1177/02676591231159513
Source: Perfusion - February 21, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Syed U Hasan Alina Pervez Arshad A Shah Syed DA Shah Muhammad Aslam Anosha Arshad Amna S Rajput M Mujeeb Zubair Source Type: research

Prehospitalization Antiplatelet Therapy and Outcomes After Saphenous Vein Graft Intervention
In conclusion, prehospital use of antiplatelet therapy was associated with a lower occurrence of major adverse cardiac events after SVG intervention. We did not find that DAPT improved outcomes compared to single antiplatelet therapy.
Source: The American Journal of Cardiology - October 26, 2012 Category: Cardiology Authors: Ralf E. Harskamp, Marcel A. Beijk, Peter Damman, Jan G. Tijssen, Renato D. Lopes, Robbert J. de Winter Tags: Coronary Artery Disease Source Type: research

Rationale and Design of the On‐Treatment PLAtelet Reactivity‐Guided Therapy Modification FOR ST‐Segment Elevation Myocardial Infarction (PLATFORM) Randomized Trial
ConclusionPLATFORM will determine whether the platelet reactivity‐guided use of ticagrelor in combination with 200 mg aspirin, compared with standard antiplatelet regimen, improves clinical outcome in moderate to high‐risk STEMI patients undergoing PPCI. Clinical Trial RegistrationU.S. National Institutes of Health (NIH) at www.clinicaltrials.gov. ClinicalTrials.gov Identifier: NCT01739556, and Current Controlled Trials at www.controlledtrials.com. International Standard Randomized Controlled Trial Number ISRCTN83081599.
Source: Journal of Interventional Cardiology - December 1, 2012 Category: Cardiology Authors: IGOR MRDOVIC, LIDIJA SAVIC, GORDANA KRLJANAC, MILIKA ASANIN, NATASA CVETINOVIC, NATASA BRDAR, MILENA STOJANOVIC, NEMANJA DJURICIC, SANJA STANKOVIC, JELENA MARINKOVIC, JOVAN PERUNICIC Tags: Randomized Trial Source Type: research

Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
Conclusions: Prior-CABG patients presenting with acute coronary syndrome are a high-risk cohort for death and recurrent cardiovascular events but have a lower risk for major bleeding. Similar to the results in no-prior-CABG patients, ticagrelor was associated with a reduction in ischemic events without an increase in major bleeding.
Source: American Heart Journal - July 29, 2013 Category: Cardiology Authors: Emmanouil S. Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann, Lars Wallentin, Stefan K. James Tags: Acute Ischemic Heart Disease Source Type: research

Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial
Conclusions: Clopidogrel is safer than ticagrelor in regard to bleeding. Additionally, ticagrelor's purported faster antiplatelet ‘offset’ is substantially longer than its pharmacokinetics indicate. Considering the fact that the mortality, stent thrombosis and myocardial infarction ‘benefit’ of ticagrelor have recently been challenged, and that the increase in stroke on ticagrelor has recently been shown to be worse than originally published, the decision to use ticagrelor over clopidogrel in the face of a higher risk for bleeds is not advised.
Source: International Journal of Cardiology - July 31, 2013 Category: Cardiology Authors: James J. DiNicolantonio, Fabrizio D'Ascenzo, Ales Tomek, Saurav Chatterjee, Asfandyar K. Niazi, Giuseppe Biondi-Zoccai Tags: Editorials Source Type: research